latest news stock values companies glp-1 obesity cardiometabolic The rate in the US fell in 2023 as GLP-1s go mainstream GLP-1 Prescriptions Quadruple Since 2021

For a deep dive, see our article Orforglipron Canada: Update On the Newest Weight Loss Pill

Of course, trying to optimize your nutrition, exercise, and behaviors is always the basis of any weight loss program, Lofton says

Advocacy groups and grieving parents continue to call for stronger safeguards to prevent what they describe as a digital drug market targeting young users

In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]

Palantir and Tampa General partner on innovation to enhance hospital tech